Chemotherapy market seen reaching $80.45 billion by 2035

Market Research Future projects the global chemotherapy market will grow from $35.24 billion in 2026 to $80.45 billion by 2035, driven by rising cancer incidence, cheaper biosimilar and generic drugs, and a shift toward oral treatments. The report also points to strong government support in the U.S., Europe, China, India and Brazil as a key reason the market keeps expanding.

Why it matters: - The chemotherapy market remains a core part of oncology care even as targeted therapies and immuno-oncology drugs expand. - Market Research Future projects the global market will rise to $80.45 billion by 2035 from $35.24 billion in 2026, a trajectory that reflects continuing demand for first-line and salvage treatment. - The shift matters for hospitals, payers and patients because lower-cost drugs and more oral options can widen access and reduce infusion-center pressure.

What happened: - Market Research Future said the global chemotherapy market was estimated at $32.18 billion in 2025. - The firm forecast 10.21% compound annual growth from 2026 through 2035. - The report links the growth outlook to higher cancer incidence, lower treatment costs from generic and biosimilar adoption, and more oral cytotoxic formulations. - The report also highlighted government support in the EU, India, China and Brazil as a demand driver. - Request a free sample of the report.

The details: - WHO estimates cited in the report point to 20 million new cancer cases annually by 2025. - GLOBOCAN 2024 data project 35 million new cancer diagnoses a year by 2050. - The report says chemotherapy remains important for about 60% of solid-tumor patients who do not respond to precision therapies alone. - Europe’s tender systems for platinum-based drugs have lowered per-cycle infusion costs through generic competition. - The report says treatment costs have fallen 30% to 45% in some settings. - Oral antineoplastics held a 54.3% share of the market by route of administration in 2025. - Alkylating agents were the largest drug class in 2025 with about 40.8% share. - Antimetabolites were the fastest-growing drug class, with a projected 10.75% CAGR from 2026 to 2035. - Intravenous chemotherapy was the fastest-growing route, forecast at 10.85% CAGR through 2035. - Lung cancer led indications with about 27.8% share in 2025. - Breast cancer was the fastest-growing indication, projected at 10.95% CAGR. - Hospitals and clinics were the largest end-user segment. - Specialty centers were the fastest-growing end-user segment.

Between the lines: - The report suggests chemotherapy is shifting from a purely hospital-based service model to a broader care network that includes community centers and at-home treatment. - Oral drugs are gaining share because they can reduce chair time, nursing burden and the need for repeated infusion visits. - The competitive picture remains mixed, with branded drug portfolios, biosimilars and generic manufacturers all pushing different parts of the market. - The report describes the market as moderately concentrated, with the top five companies holding a combined 35% to 42% revenue share. - Regional policy is doing a lot of the heavy lifting. Public reimbursement, procurement systems and cancer-center investments are expanding access at scale.

What’s next: - The report expects AI-driven precision dosing tools to become more common by 2030. - It says oral chemotherapy will likely become the default first-line option for more indications. - Supply-chain regionalization and domestic API manufacturing are expected to gain momentum in the U.S., EU and Japan. - The report also expects more market consolidation around antibody-drug conjugate hybrid regimens. - Read the full report

The bottom line: - Chemotherapy is not fading from oncology. The market is still growing fast because cancer incidence is rising, access is widening and treatment is moving toward lower-cost, more flexible delivery models.